Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

181. Global Strategy for Diagnosis, Management, and Prevention of COPD

Global Strategy for Diagnosis, Management, and Prevention of COPD Pulmonary Perspective GlobalStrategyfortheDiagnosis,Management,and PreventionofChronicObstructivePulmonaryDisease GOLD Executive Summary Jørgen Vestbo 1,2 , Suzanne S. Hurd 3 , Alvar G. Agusti ´ 4 , Paul W. Jones 5 , Claus Vogelmeier 6 , Antonio Anzueto 7 , Peter J. Barnes 8 , Leonardo M. Fabbri 9 , Fernando J. Martinez 10 , Masaharu Nishimura 11 , Robert A. Stockley 12 , Don D. Sin 13 , and Roberto Rodriguez-Roisin 4 1 (...) of Texas Health Science Center, San Antonio, Texas; 8 National Heart and Lung Institute, London, United Kingdom; 9 University of Modena and Reggio Emilia, Modena, Italy; 10 University of MichiganSchoolofMedicine,AnnArbor,Michigan; 11 HokkaidoUniversitySchoolofMedicine,Sapporo,Japan; 12 UniversityHospitalsBirmingham, Birmingham, United Kingdom; and 13 St Paul’s Hospital, Vancouver, Canada Chronic obstructive pulmonary disease (COPD) is a global health problem,andsince2001

2015 European Respiratory Society

182. Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis

Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis X XIE, M WANG, A SCHAINK (...) , M KRAHN FEBRUARY 2015 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness

2015 Health Quality Ontario

183. Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD

Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Hand-held Fourier transform (...) infrared (FTIR) spectroscopy to diagnose and monitor COPD. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives The hand-held Fourier transform infrared (FTIR) spectroscopy device, developed by Glyconics Ltd., analyses the composition of sputum from patients with chronic obstructive pulmonary disease (COPD), to diagnose and monitor the disease. The device is intended to be used in the home by health professionals, as well as in primary care

2015 Health Technology Assessment (HTA) Database.

184. BuddyWOTCHT to monitor COPD

BuddyWOTCHT to monitor COPD BuddyWOTCH™ to monitor COPD BuddyWOTCH™ to monitor COPD NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. BuddyWOTCH™ to monitor COPD. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives BuddyWOTCH™ is a smartwatch that can be worn all the time at home (...) to monitor the health of patients with chronic obstructive pulmonary disease (COPD). It has sensors that record walking, oxygen levels in the blood, temperature and heart rate. The developer says it can detect and warn the patient of a COPD 'flare-up', so that they can access treatments quicker. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Monitoring, Physiologic; Pulmonary Disease, Chronic Obstructive Language Published English Country of organisation England

2015 Health Technology Assessment (HTA) Database.

185. Executive Summary: Prevention of Acute Exacerbation of COPD

Executive Summary: Prevention of Acute Exacerbation of COPD 883 journal.publications.chestnet.org E x e c u t i v e S umm a r y Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP (...) - 893 ABBREVIATIONS : AEC O P D 5 ac u t e exacerba tio n o f C O PD ; C D C 5 US C en t er s f o r Dis e as e C o n t r o l a n d P r e v en tio n ; CHES T 5 Amer ica n C o lleg e o f Chest Ph ysicia n s ; CT S 5 Canadian Th oracic S o ciety ; WH O 5 W o r l d H e a l t h Or ga niza tio n COPD is a common disease with substantial associated morbidity and mortality. Patients with COPD usually have a progression of airfl ow obstruction that is not fully reversible and can lead to a history of progres

2015 American College of Chest Physicians

186. Prevention of Acute Exacerbations of COPD

Prevention of Acute Exacerbations of COPD 894 Evidence-Based Medicine [ 147#4 CHEST APRIL 2015 ] P r e v en tio n o f A c u t e Exacerba tio n s o f C O PD American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP ; Pat G. Camp (...) , PhD, PT ; Bartolome R. Celli , MD, FCCP ; Gail Dechman , PhD, PT ; Mark T. Drans? eld , MD ; Stanley B. Fiel , MD, FCCP ; Marilyn G. Foreman , MD, FCCP ; Nicola A. Hanania , MD, FCCP ; Belinda K. Ireland , MD ; Nathaniel Marchetti , DO, FCCP ; Darcy D. Marciniuk , MD, FCCP ; Richard A. Mularski , MD, MSHS, MCR, FCCP ; Joseph Ornelas , MS ; Jeremy D. Road , MD ; and Michael K. Stickland , PhD BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as well as throughout

2015 American College of Chest Physicians

187. Randomised controlled trial: Discontinuing inhaled steroids might not be safe in severe COPD cases

Randomised controlled trial: Discontinuing inhaled steroids might not be safe in severe COPD cases Discontinuing inhaled steroids might not be safe in severe COPD cases | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Discontinuing inhaled steroids might not be safe in severe COPD cases Article Text Therapeutics/Prevention Randomised controlled trial Discontinuing inhaled steroids might not be safe in severe COPD cases Rafael

2015 Evidence-Based Medicine (Requires free registration)

188. Olodaterol (as hydrochloride) (Striverdi Respimat) - as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD)

Olodaterol (as hydrochloride) (Striverdi Respimat) - as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD) Final Appraisal Recommendation Advice No: 3614 – November 2014 Olodaterol (as hydrochloride) (Striverdi ® Respimat ® ? ) 2.5 microgram solution for inhalation Submission by Boehringer Ingelheim Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number (...) November 2014 Last reviewed June 2018 Recommendation of AWMSG Olodaterol (as hydrochloride) (Striverdi ® Respimat ® ? ) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD). Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3614: Olodaterol

2015 All Wales Medicines Strategy Group

189. Self-care support for people with COPD

Self-care support for people with COPD Self-care support for people with COPD Self-care support for people with COPD Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Centre for Reviews and Dissemination. Self-care support for people with COPD. University of York. Evidence briefings. 2014 Authors (...) ' conclusions As the prevalence of long-term conditions increases there is a greater focus on encouraging people to manage their condition(s). Self-care has been identified as integral to maintaining the health and wellbeing of people with COPD. There is consistent evidence that multicomponent interventions reduce respiratory-related hospital admissions and improve quality of life for people with COPD. Multicomponent interventions that include action plans, exercise, education and smoking cessation

2014 Health Technology Assessment (HTA) Database.

190. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. (PubMed)

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD (...) received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period. The primary end point was the time to the first moderate or severe COPD exacerbation. Spirometric findings, health status, and dyspnea were also

Full Text available with Trip Pro

2014 NEJM

191. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. (PubMed)

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD (...) received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period. The primary end point was the time to the first moderate or severe COPD exacerbation. Spirometric findings, health status, and dyspnea were also

Full Text available with Trip Pro

2014 NEJM

192. Stepping Down Therapy in COPD. (PubMed)

Stepping Down Therapy in COPD. 25196116 2014 10 14 2018 12 02 1533-4406 371 14 2014 Oct 02 The New England journal of medicine N. Engl. J. Med. Stepping down therapy in COPD. 1340-1 10.1056/NEJMe1409219 Reilly John J JJ From the Department of Medicine, University of Pittsburgh, Pittsburgh. eng Editorial Comment 2014 09 08 United States N Engl J Med 0255562 0028-4793 0 Androstadienes 0 Bronchodilator Agents 0 Glucocorticoids 0 Scopolamine Derivatives 6EW8Q962A5 Salmeterol Xinafoate CUT2W21N7U

2014 NEJM

193. Performance of the BODE index in patients with alpha1-antitrypsin deficiency-related COPD (PubMed)

Performance of the BODE index in patients with alpha1-antitrypsin deficiency-related COPD The BODE (body mass index, airflow obstruction, dyspnoea and exercise capacity) index is used to decide on referral and transplantation of patients with chronic obstructive pulmonary disease (COPD). The BODE index has not been validated in patients with α1-antitrypsin deficiency, who account for 15% of COPD patients undergoing lung transplantation. We sought to validate the BODE index in α1-antitrypsin (...) deficiency-related COPD. We assessed the prognostic value of the BODE index in 191 patients followed from 2006 to 2012 in a French prospective cohort of patients with α1-antitrypsin deficiency. 20 patients died during follow-up and 22 underwent lung transplantation. Survival (95% CI) was 93.0% (91.7-94.3%) at 3 years and 76.0% (72.9-79.1%) at 5 years. The 3-year survival was 97.4% (96.6-98.2%), 98.0% (96.7-99.3%), 87.7% (84.5-90.9%) and 75.3% (66.0-84.6%) for patients with BODE index 0-2, 3-4, 5-6 and 7

Full Text available with Trip Pro

2014 EvidenceUpdates

194. What are the benefits and risks of inhaled corticosteroids for COPD?

What are the benefits and risks of inhaled corticosteroids for COPD? What are the benefits and risks of inhaled corticosteroids for COPD? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What are the benefits and risks of inhaled corticosteroids for COPD? View/ Open Date 2014-05 Format Metadata Abstract Q: What (...) are the benefits and risks of inhaled corticosteroids for COPD? A: Inhaled corticosteroids (ICS), either alone or with a long-acting [beta] agonist (LABA), reduce the frequency of exacerbations of chronic obstructive pulmonary disease (COPD) and statistically, but not clinically, improve quality of life (QOL) (strength of recommendation [SOR]: B, meta-analyses of heterogeneous studies). However, ICS have no mortality benefit and don’t consistently improve forced expiratory volume in 1 second (FEV1) (SOR: B

2014 Clinical Inquiries

195. Ultibro Breezhaler (Indacaterol maleate, glycopyrronium bromide) - COPD

Ultibro Breezhaler (Indacaterol maleate, glycopyrronium bromide) - COPD HAS - Medical, Economic and Public Health Assessment Division 1/24 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 7 May 2014 ULTIBRO BREEZHALER 85 µg/43 µg, inhalation powder, hard capsule B/6 hard capsules + 1 inhaler (CIP: 34009 275 662 4 0) B/30 hard capsules + 1 inhale (CIP: 34009 275 664 7 9) Applicant: NOVARTIS INN Indacaterol maleate, glycopyrronium bromide ATC Code (2013 (...) /24 Actual benefit In patients with COPD: - Substantial AB only in patients with moderate to very severe COPD whose symptoms are already controlled by the separately administered indacaterol and glycopyrronium combination; - Insufficient AB for reimbursement by National Health Insurance in the other cases. Improvement in actual benefit ULTIBRO BREEZHALER fixed-dose indacaterol and glycopyrronium combination does not provide any improvement in actual benefit (IAB V, non-existent) compared

2014 Haute Autorite de sante

196. Aclidinium in the management of COPD. Besides an anticholinergic agent, what else do we know about this drug?

Aclidinium in the management of COPD. Besides an anticholinergic agent, what else do we know about this drug? 2014. DAR No 1. Aclidinium, as maintenance therapy in the management of COPD (Bretaris Genuair®, Eklira Genuair®) - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 1. Aclidinium, as maintenance therapy in the management of COPD (Bretaris Genuair®, Eklira Genuair®) DAR No 1. Aclidinium, as maintenance therapy in the management (...) of COPD (Bretaris Genuair®, Eklira Genuair®) Content tools Share it Besides an anticholinergic agent, what else do we know about this drug? There is no head-to-head trial comparing aclidinium vs other long-acting bronchodilators. Compared to placebo, aclidinium 400 mcg/12h improves spirometry parameters although the clinical relevance of this improvement is modest. Adverse effects related to heart conduction have been reported, and the EMA has requested a post-approval study to monitor cardiovascular

2014 Drug and Therapeutics Bulletin of Navarre (Spain)

197. Should you consider antibiotics for exacerbations of mild COPD?

Should you consider antibiotics for exacerbations of mild COPD? Should you consider antibiotics for exacerbations of mild COPD? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Should you consider antibiotics for exacerbations of mild COPD? View/ Open Date 2014-04 Format Metadata Abstract Consider antibiotics (...) for patients with exacerbations of mild to moderate chronic obstructive pulmonary disease (COPD). URI Part of Citation Journal of Family Practice, 64(4): 2014: E11-E13 Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2014 PURLS

198. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index (PubMed)

Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index No valid tools exist for evaluating the prognosis in the short and medium term after hospital discharge of patients with COPD. Our hypothesis was that a new index based on the CODEX (comorbidity, obstruction, dyspnea, and previous severe exacerbations) index can accurately predict mortality, hospital readmission, and their combination for the period from 3 months to 1 year after discharge (...) in patients hospitalized for COPD.A multicenter study of patients hospitalized for COPD exacerbations was used to develop the CODEX index, and a different patient cohort was used for validation. Comorbidity was measured using the age-adjusted Charlson index, whereas dyspnea, obstruction, and severe exacerbations were calculated according to BODEX (BMI, airfl ow obstruction, dyspnea, and previous severe exacerbations) thresholds. Information about mortality and readmissions for COPD or other causes

2014 EvidenceUpdates

199. Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy (PubMed)

Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy Endobronchial valve (EBV) therapy may be associated with improvements in chronic obstructive pulmonary disease-related outcomes and may therefore be linked to improvements in the body mass index, airflow obstruction, dyspnoea, exercise capacity (BODE) index. Data from 416 patients with advanced emphysema and hyperinflation across Europe and USA, who were randomised to EBV (n=284) or conservative therapy (n

Full Text available with Trip Pro

2014 EvidenceUpdates

200. The Impact of Coexisting COPD on Survival of Patients With Early-Stage Non-small Cell Lung Cancer Undergoing Surgical Resection (PubMed)

The Impact of Coexisting COPD on Survival of Patients With Early-Stage Non-small Cell Lung Cancer Undergoing Surgical Resection COPD is a recognized risk factor for lung cancer, but studies of coexisting COPD in relation to lung cancer outcomes are limited. We assessed the impact of COPD on overall survival (OS) and progression-free survival (PFS) in patients with early-stage non-small cell lung cancer (NSCLC).Patients (N = 902) with early-stage (stage IA-IIB) NSCLC treated with surgical (...) resection were retrospectively analyzed. The association of self-reported, physician-diagnosed COPD with survivals of NSCLC was assessed using the log-rank and Cox regression models, adjusting for age, sex, BMI, smoking, stages, and performance status.Among this cohort of patients with NSCLC, 330 cases had physician-diagnosed COPD, and 572 did not have COPD. The 5-year OS in patients with COPD (54.4%) was significantly lower (P = .0002) than that in patients without COPD (69.0%). The 5-year PFS rates

Full Text available with Trip Pro

2014 EvidenceUpdates